Journal of Oncology / 2020 / Article / Tab 2

Research Article

Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis

Table 2

Characteristics of 124 TNBC patients assessed for BRCA1/2 mutations.

FactorPatients tested for BRCA mutations value (BRCA-positive vs BRCA-negative)
BRCA noncarriersRate (%)BRCA carriersRate (%)

Number of patients9410030100

Age at diagnosis (years)
Median49400.0115
Mean47.541.4
Range25–6724–76

Clinical staging (cTNM)
I2324.514470.0006
II51541343
III192027
IV1<0.513

Initial clinical tumor staging
cT000000.0004
cT128301653
cT25659.5930
cT34427
cT466.5310
No available data0000

Initial clinical node staging
cN05558.519630.1063
cN12728.51033
cN299.514
cN333.500
No available data0000

HER2 expression
0 or 1+798429970.0091
2+, FISH negative151613

Histological type
NST8021700.0023
Lobular58513.5
Medullar55.513.5
Apocrine25.513.5
Metaplastic2226
Others02413.5

G
10026.50.0065
229301240
364681653.5
No available data1200

Ki-67 expression
<14%2627.5516.50.0761
14–30%29311033.5
>30%28301343.5
No available data1111.526.5

Vimentin expression assessed
Yes82872686.50.8361
No1213413.5

Vimentin
Positive1415826.50.0372
Negative68851873.5

Contralateral breast cancer1314826.50.0228
Other primary cancer (other than contralateral breast cancer)99.5516.50.1475

FISH: fluorescence in situ hybridization.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.